文献速递神经肿瘤

残留颅内脑膜瘤的体积增长与生长曲线分析

Volumetric Growth and Growth Curve Analysis of Residual Intracranial Meningioma.
PubMed 文献 · Neurosurgery · 2022-12-14

该研究回顾性分析了2004至2020年间在一家三级神经外科中心识别的236例残留脑膜瘤患者,采用手动分割测量术后及每次随访MRI的肿瘤体积。中位随访5.3年间,绝对增长率为每年0.11 cm³,相对增长率为每年4.3%;56.0%的患者按RANO标准(体积增加40%)判定为进展,颅底位置(HR 1.60)和Ki-67指数升高(HR 3.43)与进展相关。

要点

  • 残留脑膜瘤绝对增长率每年0.11 cm³,相对增长率每年4.3%。
  • 56.0%患者按RANO标准进展,仅5.5%出现临床进展。
  • 颅底位置(HR 1.60)和Ki-67指数升高(HR 3.43)与进展相关。

核心结论

  • 残留脑膜瘤的绝对和相对增长率较低,但多数符合RANO进展标准。
  • 肿瘤位置和Ki-67指数可用于分层辅助治疗和监测方案。

研究设计与样本

  • 回顾性队列研究,纳入2004至2020年间在一家三级神经外科中心识别的残留脑膜瘤患者236例。
  • 肿瘤体积通过手动分割测量,术后及每次随访MRI均进行测量。
  • 增长率采用线性混合效应模型和非线性回归分析生长轨迹确定。
  • 进展根据RANO标准(体积增加40%)定义。

主要发现

  • 236例残留脑膜瘤患者中,132例(56.0%)按RANO标准进展,其中86例(65.2%)进展后接受保守管理。
  • 13例(5.5%)出现临床进展。
  • 中位随访5.3年(四分位距3.5-8.6年)期间,绝对增长率为每年0.11 cm³,相对增长率为每年4.3%。
  • 多变量Cox回归分析中,与残留脑膜瘤进展相关的因素为颅底位置(风险比[HR] 1.60,95%CI 1.02-2.50)和Ki-67指数升高(HR 3.43,95%CI 1.19-9.90)。
  • 大多数脑膜瘤呈现指数和逻辑斯蒂生长模式(中位R²值0.84,95%CI 0.60-0.90)。

关键数值与推荐

  • 进展定义:RANO标准,即体积增加40%。
  • 绝对增长率:每年0.11 cm³;相对增长率:每年4.3%。
  • 颅底位置:HR 1.60(95%CI 1.02-2.50);Ki-67指数升高:HR 3.43(95%CI 1.19-9.90)。
  • 生长模式拟合中位R²值0.84(95%CI 0.60-0.90)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After meningioma surgery, approximately 1 in 3 patients will have residual tumor that requires ongoing imaging surveillance. The precise volumetric growth rates of these tumors are unknown. OBJECTIVE: To identify the volumetric growth rates of residual meningioma, growth trajectory, and factors associated with progression. METHODS: Patients with residual meningioma identified at a tertiary neurosurgery center between 2004 and 2020 were retrospectively reviewed. Tumor volume was measured using manual segmentation, after surgery and at every follow-up MRI scan. Growth rates were ascertained using a linear mixed-effects model and nonlinear regression analysis of growth trajectories. Progression was defined according to the Response Assessment in Neuro-Oncology (RANO) criteria (40% volume increase). RESULTS: There were 236 patients with residual meningioma. One hundred and thirty-two patients (56.0%) progressed according to the RANO criteria, with 86 patients being conservatively managed (65.2%) after progression. Thirteen patients (5.5%) developed clinical progression. Over a median follow-up of 5.3 years (interquartile range, 3.5-8.6 years), the absolute growth rate was 0.11 cm 3 per year and the relative growth rate 4.3% per year. Factors associated with residual meningioma progression in multivariable Cox regression analysis were skull base location (hazard ratio [HR] 1.60, 95% CI 1.02-2.50) and increasing Ki-67 index (HR 3.43, 95% CI 1.19-9.90). Most meningioma exhibited exponential and logistic growth patterns (median R 2 value 0.84, 95% CI 0.60-0.90). CONCLUSION: Absolute and relative growth rates of residual meningioma are low, but most meet the RANO criteria for progression. Location and Ki-67 index can be used to stratify adjuvant treatment and surveillance paradigms.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Gillespie CS, Richardson GE, Mustafa MA, et al. Volumetric Growth and Growth Curve Analysis of Residual Intracranial Meningioma. Neurosurgery. 2022. PMID: 36656062. doi:10.1227/neu.0000000000002268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。